歌礼制药公布ASC30每日一次口服片美国Ib期多剂量递增研究数据

Core Insights - The announcement from the company indicates positive topline pharmacokinetic (PK) data from the Phase Ib multiple ascending dose (MAD) study of ASC30 in obese subjects with a BMI of 30-40 kg/m² [1] Group 1: Study Results - The study involved a randomized, double-blind, placebo-controlled design [1] - In cohort 1 (20 mg), the drug exposure at steady state reached 3560 ng.h/mL, while in cohort 2 (40 mg), it reached 5060 ng.h/mL [1] - After 28 days of treatment, the average weight loss was 4.5% for cohort 1 and 6.5% for cohort 2, indicating that higher drug exposure correlates with more significant weight loss effects [1]